Table 3.
Comparison between parameters determined after NMU-induced breast cancer in various races of rats tothe current study
| Row | Race | NMU dosage (mg/kg) and injection type | Age at first injection (days) | No. of injections | Time between injections (days) | LP | TI | TM | Histology results | References, Year |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sprague-Dawley | 50, IP | 50 | 3 | 30 | 82 | 88.4%, metastasis to liver, spleen, and lung | 4.4 | 83.4% carcinoma | 30.1998 |
| 2 | Sprague Dawley | 37.5/50, IP | 50 | 1 | - | 60 | 55% /75.9% | 1.08 ± 0.22 / 2.0 ± 0.35 | Carcinoma, papilloma, hyperplasia, carcinoma-in situ | 46.1998 |
| 3 | Sprague Dawley | 50, IP | 50 | 2 | 7 | - | - | - | - | 38.2000 |
| 4 | Sprague-Dawley | 50, IP | 55 | 1 | - | - | - | - | - | 32.2000 |
| 5 | Sprague Dawley | 50, IP | 50 | 1 | - | 63.70 | 55% | 1.3 | Adenocarcinoma | 43.2001 |
| 6 | Virgin Wistar | 50, IP | 50 | 3 | 30 | 113.0 ± 4.2 | 60% | - | - | 28.2004 |
| 7 | Wistar | 50, IV | 50-55 | 3 | 28 | - | - | - | - | 31.2004 |
| 8 | Wistar-furth | 50, IP | 52 | 1 | - | 140 | 77% | - | Adenocarcinoma | 37.2004 |
| 9 | Virgin wistar | 50, IP | 50 | 3 | 30 | 113 ± 4.2 | 60% | 1.93 ± 0.4 | - | 27.41.2005.2008 |
| 10 | Virgin Sprague Dawley | 50,IP | 50 | 1 | - | - | 93.3% | 4.0 | - | 44.2005 |
| 11 | Sprague Dawley | 50, tail vein injection | 50 | 1 | - | 78 ± 0.9 | 83.3% | 4.87 ± 0.77 | Ductal carcinoma in situ | 42.2005 |
| 12 | Sprague Dawley | 50, IP | 50 | 3 | 50.38 | 100 | - | 2 ± 0.63 | - | 36.2005 |
| 13 | Sprague Dawley | 50, IP | 50 | 1 | - | 63-70 | 55% | 1.3 | Adenocarcinoma | 33.2005 |
| 14 | Lewis, Fischer 344, Wistarfurth, Copenhagen | 50, IP | 49 | 1 | - | Le: 91, F: 168 W: 252, C: 355 | - | - | - | 29.2006 |
| 15 | Sprague Dawley | 40,tail vein injection | 45 | 1 | - | 59.5 | 100% with 5% metastasis | 4.65 | Adenocarcinoma, fibroadenoma and tubular adenoma | 34.2006 |
| 16 | Wistar | 50 | 45 | 2 | 7 | 90-120 | 45% | 0.5 | Adenocarcinoma | 45.2007 |
| 17 | Sprague Dawley | 50, IP | 42 | 2 | 8 | 103.09 ± 7.32 | 55.00% ± 11.41 | 1.64 ± 0.39 | - | 40.2007 |
| 18 | Wistar-furth | 50/35, IP | 50 | 50 | - | 80 ± 2.39 | - | - | Ductal carcinoma in situ (DCIS | 39.2007 |
| 19 | Virgin Wistar | 50, IP | 50 | 3 | 7 | Up to 210 | 71% | 1.6 | Carcinoma | 4.2008 |
| 20 | Copenhagen | 50, IP | 50-55 | 1 | - | 90-270 | 5% | - | Adenocarcinoma | 47.2008 |
| 21 | Sprague Dawley | 50, IP | 21 | 1 | - | 35 | - | 4.8 ± 0.6 | Adenocarcinomas (papillary, cribriform, | 35.2009 |
| 22 | Sprague Dawley | 50, IP | 50 | 1 | - | 80 | 80% | 2.5 ± 0.34 | Adenocarcinoma,benign tumors | 1.2009 |
| 23 | Wistar albino | 50, IP | 50 | 3 | 14 | 150 ± 56.58 | 65% without metastasis | 1.43 ± 0.53 | 91.9% adenocar cinoma | Current study |